{"denomUnitsSelected":"Participants","description":"TTP was defined as the time from the date of the first dose until the earliest date of confirmed PD per IMWG, or death due to PD. PD: increase of \\>=25% from lowest response value in any one or more of the following: serum M-component increase \\>=0.5 g/dL or urine M-component increase \\>=200 mg/24-hour; difference between involved and uninvolved FLC levels increase must be \\>10 mg/dL; bone marrow plasma cell \\>=10%; definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas; development of hypercalcemia that can be attributed solely to plasma cell proliferative disorder.","reportingStatus":"NOT_POSTED","timeFrame":"Up to 16.7 months","title":"Groups 2 and 3: Time to Progression (TTP)","type":"SECONDARY"}